Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer
NCT ID NCT04740307
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This clinical trial is testing a combination of two drugs—an immunotherapy (pembrolizumab/quavonlimab) and a targeted therapy (lenvatinib)—as a first treatment for people with advanced hepatocellular carcinoma, a type of liver cancer that cannot be removed by surgery. The study aims to see if this combination is safe and can shrink tumors. Participants receive the drugs intravenously and orally, and researchers monitor side effects and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab/quavonlimab (immunotherapy) plus lenvatinib (targeted therapy)
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with advanced liver cancer, potentially shrinking tumors and extending life.
What could go wrong
This is a mid-stage trial with a small number of participants, so results may not apply to everyone. The combination may cause significant side effects, including immune-related reactions and liver toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Hospital ( Site 0113)
Hefei, Anhui, 230071, China
-
Asan Medical Center ( Site 0289)
Seoul, 05505, South Korea
-
Beijing Cancer hospital-Department of Hepato-Pancreato-Biliary Surgery II ( Site 0107)
Beijing, Beijing Municipality, 100142, China
-
Blue Ridge Cancer Care ( Site 0008)
Roanoke, Virginia, 24014, United States
-
CHUV (centre hospitalier universitaire vaudois) ( Site 0333)
Lausanne, Canton of Vaud, 1011, Switzerland
-
Cantonal Hospital St.Gallen-Klinik für Gastroenterologie / Hepatologie ( Site 0334)
Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
-
Charleston Oncology ( Site 0003)
Charleston, South Carolina, 29414, United States
-
City of Hope Comprehensive Cancer Center ( Site 0002)
Duarte, California, 91010, United States
-
Fuzhou General hospital of Nanjing Military Command-Oncology Department ( Site 0105)
Fuzhou, Fujian, China
-
Hiroshima University Hospital ( Site 0156)
Hiroshima, 734-8551, Japan
-
Hospital Universitari Vall d'Hebron-Liver Unit - Department of Internal Medicine ( Site 0310)
Barcelona, 08035, Spain
-
Hospital Universitario Central de Asturias-Hepatology ( Site 0309)
Oviedo, Principality of Asturias, 33011, Spain
-
Huashan Hospital Affiliated Fudan University-Surgery Department ( Site 0118)
Shanghai, Shanghai Municipality, 200040, China
-
Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0231)
Rozzano, Milano, 20089, Italy
-
Hunan Cancer Hospital-intervention department ( Site 0109)
Changsha, Hunan, 410013, China
-
Hôpitaux Universitaires de Genève (HUG) ( Site 0335)
Geneva, Canton of Geneva, 1211, Switzerland
-
Icahn School of Medicine at Mount Sinai ( Site 0009)
New York, New York, 10029, United States
-
Inselspital Bern-Universitätsklinik für Viszerale Chirurgie und Medizin ( Site 0331)
Bern, 3010, Switzerland
-
Istituto Nazionale Tumori IRCCS Fondazione Pascale-Department of Abdominal Oncology ( Site 0230)
Naples, 80131, Italy
-
Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - GI and Immunology ( Site 0013)
Baltimore, Maryland, 21287, United States
-
Kindai University Hospital- Osakasayama Campus-Department of Gastroenterology and Hepatology ( Site
Sayama, Osaka, 589-8511, Japan
-
NATIONAL CHENG-KUNG UNI. HOSP.-Clinical Trial Research Team of Liver Diseases ( Site 0354)
Tainan, 704, Taiwan
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Onkologii i Radioterapii ( Site
Warsaw, Masovian Voivodeship, 02-034, Poland
-
National Cancer Center Hospital East ( Site 0153)
Kashiwa, Chiba, 2778577, Japan
-
National Taiwan University Hospital-Oncology ( Site 0351)
Taipei, 10002, Taiwan
-
Oregon Health and Science University ( Site 0006)
Portland, Oregon, 97239, United States
-
Ospedale San Raffaele-Oncologia Medica ( Site 0227)
Milan, 20132, Italy
-
Samsung Medical Center ( Site 0288)
Seoul, Kyonggi-do, 06351, South Korea
-
Seoul National University Bundang Hospital-Medical Oncology ( Site 0290)
Seongnam, Kyonggi-do, 13620, South Korea
-
Southern Medical University Nanfang Hospital-Liver Cancer Department ( Site 0106)
Guangzhou, Guangdong, 510515, China
-
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0246)
Koszalin, West Pomeranian Voivodeship, 75-581, Poland
-
Taipei Veterans General Hospital-Division of Gastroenterology & Hepatology, Department of Medicine (
Taipei, 112201, Taiwan
-
The First Affiliated Hospital of Xian Jiaotong University ward1 depattment of medical oncology ( Sit
Xi'an, Shaanxi, 710061, China
-
Toranomon Hospital Kajigaya ( Site 0154)
Kawasaki, Kanagawa, 213-8587, Japan
-
UniversitätsSpital Zürich-Gastroenterologie & Hepatologie ( Site 0332)
Zurich, Canton of Zurich, 8091, Switzerland
-
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0247)
Gdansk, Pomeranian Voivodeship, 80-952, Poland
-
Virginia Mason Medical Center ( Site 0004)
Seattle, Washington, 98101, United States
-
Wojewódzki Szpital im. Św. Ojca Pio w Przemyślu ( Site 0249)
Przemyśl, Podkarpackie Voivodeship, 37-700, Poland
-
Wuhan Union Hospital Cancer Center ( Site 0108)
Wuhan, Hubei, 430022, China
-
Zhongshan Hospital,Fudan University ( Site 0103)
Shanghai, Shanghai Municipality, 200032, China